- Home
- ALLR vs NEUP Comparison
ALLR vs NEUP Comparison
Compare ALLR & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- NEUP
- Stock Information
- Founded
- ALLR 2004
- NEUP 1996
- Country
- ALLR United States
- NEUP United States
- Employees
- ALLR N/A
- NEUP N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- NEUP
- Sector
- ALLR Health Care
- NEUP
- Exchange
- ALLR Nasdaq
- NEUP Nasdaq
- Market Cap
- ALLR 15.8M
- NEUP 12.7M
- IPO Year
- ALLR N/A
- NEUP N/A
- Fundamental
- Price
- ALLR $1.01
- NEUP $7.72
- Analyst Decision
- ALLR
- NEUP Strong Buy
- Analyst Count
- ALLR 0
- NEUP 1
- Target Price
- ALLR N/A
- NEUP $21.00
- AVG Volume (30 Days)
- ALLR 417.1K
- NEUP 31.1K
- Earning Date
- ALLR 08-04-2025
- NEUP 08-15-2025
- Dividend Yield
- ALLR N/A
- NEUP N/A
- EPS Growth
- ALLR N/A
- NEUP N/A
- EPS
- ALLR N/A
- NEUP 0.00
- Revenue
- ALLR N/A
- NEUP $15,662,715.00
- Revenue This Year
- ALLR N/A
- NEUP N/A
- Revenue Next Year
- ALLR N/A
- NEUP N/A
- P/E Ratio
- ALLR N/A
- NEUP $2.48
- Revenue Growth
- ALLR N/A
- NEUP N/A
- 52 Week Low
- ALLR $0.61
- NEUP $2.90
- 52 Week High
- ALLR $7.45
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- ALLR 53.22
- NEUP N/A
- Support Level
- ALLR $0.95
- NEUP N/A
- Resistance Level
- ALLR $1.08
- NEUP N/A
- Average True Range (ATR)
- ALLR 0.07
- NEUP 0.00
- MACD
- ALLR 0.01
- NEUP 0.00
- Stochastic Oscillator
- ALLR 59.39
- NEUP 0.00
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.